Mithramycin encapsulated in polymeric micelles by microfluidic technology as novel therapeutic protocol for beta-thalassemia by Capretto, Lorenzo et al.
© 2012 Capretto et al, publisher and licensee Dove Medical Press Ltd.  This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2012:7 307–324
International Journal of Nanomedicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
307
O r I g I N A L  r e s e A r C h
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJN.S25657
Mithramycin encapsulated in polymeric micelles 
by microfluidic technology as novel therapeutic 
protocol for beta-thalassemia
Lorenzo Capretto1
stefania Mazzitelli2
eleonora Brognara2
Ilaria Lampronti2
Dario Carugo1
Martyn hill1
Xunli Zhang1
roberto gambari2
Claudio Nastruzzi3
1engineering sciences, University 
of southampton, southampton, UK; 
2Department of Biochemistry and 
Molecular Biology, 3Department of 
Pharmaceutical sciences, University of 
Ferrara, Ferrara, Italy
Correspondence: Claudio Nastruzzi 
Department of Pharmaceutical sciences, 
University of Ferrara, Via Fossato di 
Mortara 17/19, Ferrara, 44121, Italy 
Tel +39 0532 455 255 
Fax +39 0532 455 953 
email nas@unife.it
Abstract: This report shows that the DNA-binding drug, mithramycin, can be efficiently 
encapsulated in polymeric micelles (PM-MTH), based on Pluronic® block copolymers, by a 
new microfluidic approach. The effect of different production parameters has been investigated 
for their effect on PM-MTH characteristics. The compared analysis of PM-MTH produced by 
microfluidic and conventional bulk mixing procedures revealed that microfluidics provides a 
useful platform for the production of PM-MTH with improved controllability, reproducibility, 
smaller size, and polydispersity. Finally, an investigation of the effects of PM-MTH, produced 
by microfluidic and conventional bulk mixing procedures, on the erythroid differentiation of both 
human erythroleukemia and human erythroid precursor cells is reported. It is demonstrated that 
PM-MTH exhibited a slightly lower toxicity and more pronounced differentiative activity when 
compared to the free drug. In addition, PM-MTH were able to upregulate preferentially γ-globin 
messenger ribonucleic acid production and to increase fetal hemoglobin (HbF)  accumulation, 
the percentage of HbF-containing cells, and their HbF content without stimulating α-globin 
gene expression, which is responsible for the clinical symptoms of β-thalassemia. These results 
represent an important first step toward a potential clinical application, since an increase in HbF 
could alleviate the symptoms underlying β-thalassemia and sickle cell anemia. In conclusion, 
this report suggests that PM-MTH produced by microfluidic approach warrants further evalu-
ation as a potential therapeutic protocol for β-thalassemia.
Keywords: microfluidics, lab-on-a-chip, design of experiments, erythroid differentiation, 
human erythroid precursor cells
Introduction
Mithramycin A (MTH), also called plicamycin, is an aureolic acid-type polyketide, 
which is normally isolated from various strains of the bacterium Streptomyces.1 MTH 
has been used clinically for many years to treat testicular carcinoma and several types 
of cancer including leukemia, as well as hypercalcemia in patients with metastatic 
bone lesions and Paget’s disease.2 The ability of MTH to bind the DNA minor groove 
is of great interest, since pharmacologically-mediated modulation of DNA/nuclear 
protein complex formation represents a promising approach to control gene expression. 
For instance, MTH was found to inhibit the binding of transcription factor Sp1 to 
its promoter,3 leading to gene transcription modulation of different genes, including 
VEGF,4 c-MYC, and ha-RAS, as well as antiapoptotic genes.5 It was also shown that 
MTH inhibited p53-mediated transcriptional responses, DNA methyltransferase, and 
the multidrug resistant gene MDR1,6 therefore putatively sensitizing tumor cells to 
chemotherapeutic agents.
International Journal of Nanomedicine 2012:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
308
Capretto et al
Furthermore, because of its ability to bind DNA, MTH 
has been proposed as a potential therapeutic agent for the 
treatment of hematological diseases such as β-thalassemia 
and sickle cell anemia. In these pathological cases, the 
rationale for using MTH relies on the pharmacologically-
mediated upregulation of the expression of human γ-globin 
genes.7,8 For instance, it has been demonstrated that MTH 
can induce erythroid differentiation of the human leukemic 
K562 cell line through the induction of γ-globin  messenger 
 ribonucleic acid (mRNA) accumulation. This data is 
particularly  important for clinic applications since even a 
moderate increase in the production of fetal hemoglobin 
(HbF) could be associated with a significant improvement 
in the clinical status of the patients.9 Moreover, it should 
be noted that, at least in vitro, the differentiative activity 
is achieved at lower concentrations with respect to those 
required for antiproliferative action.8
In spite of the above mentioned therapeutic potentials, 
the clinical use of MTH, especially as anticancer drug 
that requires higher doses, is still limited, mainly due to its 
severe side effects including gastrointestinal, hepatic, kidney, 
and bone marrow toxicity.10 One of the possible strategies 
to enhance its safety and efficacy is to develop different 
formulations of delivery systems such as  nanoparticles 
or microparticles,11 liposomes,12 and polymeric micelles 
(PMs).13 PMs are a class of polymeric nanoparticles with a 
core-shell structure that form spontaneously by self-assembly 
of amphiphilic block copolymer unimers in water. Unimer 
self-assembly occurs as a result of hydrophobic or electrostatic 
interactions between polymer segments.14 The development 
of a delivery system for MTH based on PMs could result in a 
series of advantages including controlled delivery, alteration 
of drug circulation time, changes in  cellular distribution, and 
increase in amount of drug delivered to target cells. Taken 
together, the use of PMs has been demonstrated to result in 
higher drug efficacy and lower side effects.15
In particular, the drug circulation time is increased by 
the presence of the polyethylene glycol shell. Polyethylene 
glycol chains create a highly water-bound barrier on the 
 particle surface which blocks the adhesion of opsonins 
and the subsequent recognition and phagocytosis by the 
reticuloendothelial system.16 Circulation time is additionally 
prolonged by reduced renal excretion of PMs compared 
to free drug.17 A prolonged circulation time is particularly 
beneficial when the target of drug action is represented by 
circulating and bone marrow cells, as in the case of  erythroid 
differentiating drugs.18 Another advantage of PMs that 
could be important for differentiating drugs is related to the 
enhanced permeation retention effect.19 This effect favors 
the accumulation of nanoparticles in tissues characterized 
by increased vascular permeability and impaired lymphatic 
drainage.20 The long circulating properties of PMs have been 
investigated by many authors that have demonstrated the 
potential of PMs as delivery system for different anticancer 
drugs including taxanes and doxorubicin.21–23 Several PM 
formulations have entered clinical trials for the treatment 
of tumors refractory to conventional treatments24 and colon 
and gastric cancers.25
The innovation in PM technology resides in a number 
of features that make them one of the most promising drug 
delivery systems. On the one hand, when compared to 
microparticle-based formulations, the nanoscale dimensions 
of PMs permit their intravenous administration and allow 
them to freely circulate in the blood stream.20 On the other 
hand, when compared to liposomes, which represent an 
example of nanoscale formulations (in this case constituted 
of low molecular weight amphiphils), PMs exhibit greater 
resistance to dissociation upon dilution into the blood stream. 
This advantage is particularly beneficial in reducing drug 
leakage from the delivery system.21
PMs represent an appealing formulation for MTH since 
the drug molecule presents specific attributes fitting the PMs’ 
nanoenvironment, which is characterized by a hydrophobic 
core and an outer hydrophilic shell. MTH has lipophilic 
moieties in its molecular structure; in this respect, MTH 
is relatively soluble in water, acetone, ethyl acetate, and 
methyl isobutyl ketone and soluble in lower alcohols and 
dimethyl sulfoxide (DMSO); it is slightly soluble in diethyl 
ether and benzene and insoluble in petroleum ether, carbon 
tetrachloride, and cyclohexane. MTH shows a log P of 
1.290 ± 1.454,26 suggesting a slight lipophilic nature and the 
potential to be associated in PMs. It has been demonstrated 
that the equilibrium partition coefficients of a drug between 
micelles and water strongly correlate with the drug’s octanol/
water partition coefficient.27
With respect to PM preparation, currently two main 
approaches are usually followed depending on the physi-
cochemical properties of block copolymer(s) and drug.28 
One method is based on the direct dissolving of the poly-
mer together with the drug in an aqueous environment, 
 usually involving moderately hydrophilic copolymers 
(eg,  poloxamers) that are readily soluble in water. By contrast, 
the  second approach is relevant for copolymers that are spar-
ingly soluble in water, thus a water miscible organic solvent is 
needed to dissolve both copolymer and drug. The commonly 
used solvents include DMSO, N,N- dimethylformamide, 
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 acetonitrile, tetrahydrofuran, acetone, and  dimethylacetamide. 
Subsequently, the solvents are generally removed by “bulk” 
procedures such as dialysis against water. The solvent 
removal by dialysis is usually widespread even if it may 
not be readily transposable to the industrial scale.29 In this 
method, solvent removal is  particularly crucial since it 
triggers the nanoprecipitation process and therefore the final 
PM dimensional and  entrapment characteristics.
Recently, an innovative and highly controlled procedure 
for PM preparation based on a microfluidic approach was 
described.30 This protocol allows the removal of organic 
solvent in a controlled fashion, through a fast and adjustable 
mixing process made possible by the peculiar microfluidic 
environment characteristics. By this method, the produc-
tion of PMs is robust, reproducible, and permits precise 
control of PM physicochemical characteristics, essential 
for their biopharmaceutical applications. With respect to 
 conventional bulk methods, PMs produced by microflu-
idic reactors show a number of advantages, including: 
smaller mean size, high homogeneity, and increased drug 
loading efficiency.30 Regarding PM size and size distribu-
tion, previous studies demonstrated that small PMs are 
more effective at evading scavenging from macrophages, 
exhibiting prolonged circulation in the blood stream.31 In 
addition, microfluidics does not require postprocessing 
steps, which are normally needed for “bulk” procedure to 
remove large particles or aggregates, before their in vitro 
or in vivo testing.32
The current study presents the development of an 
advanced formulation for mithramycin encapsulated in 
polymeric micelles (PM-MTH) produced by microfluidic 
technology and in vitro analysis of the formulation as a new 
therapeutic protocol for β-thalassemia. For comparison, 
PMs produced with conventional bulk methods were also 
 considered. The production parameters and their effects on 
PM characteristics were analyzed, and the effects of MTH 
association in PMs on the erythroid differentiation of both 
human erythroleukemia (K562) and human erythroid pre-
cursor cells (ErPC) were investigated. For the production 
of PM-MTH, Pluronic® F127 (BASF Chem Trade GmbH, 
Burgbernheim, Germany) was employed as a model block 
copolymer, due to its well-studied characteristics and the 
impressive safety profile that makes it Food and Drug 
Administration approved for pharmaceutical and medical 
applications, including parenteral administration.33
Taking into account the combination of advantages and 
possible complications and side effects of PMs, poly(ethylene 
oxide)–poly(propylene oxide) block copolymer micelles 
 represent an appealing alternative to other advanced drug 
delivery formulations, especially for drugs exhibiting a 
limited solubility in water. Future perspectives for their 
approval as drug formulations for human use will still need 
to overcome a number of drawbacks, the most significant of 
which appears to be the low stability of the self-assembled 
nanostructures upon dilution in the bloodstream.
Materials and methods
Materials
The polymer Pluronic® F127 (Lutrol® F127) was provided, 
as a kind gift, by BASF Chem Trade GmbH. DMSO and 
MTH were obtained from Sigma-Aldrich (Dorset, United 
Kingdom).
Fabrication of microfluidic reactors
The glass-made microfluidic reactors employed for the prepara-
tion of PMs were fabricated by a photolithography/wet etching 
procedure, as previously reported.34 Firstly, the channel pattern 
was designed by AutoCAD® drawing software (Autodesk, Inc, 
San Rafael, CA), thereafter, a negative film representing the 
optical mask was obtained by a commercial photomask producer 
(JD Photo-Tools, Oldham, Lancashire, United Kingdom). 
Crown white glass (B-270) plates (thickness of 1.5 mM) 
coated with a thin layer of chromium metal mask plus an 
upper layer of positive photoresist (AZ 1500; Telic Company, 
Valencia, CA) were used for channel network fabrication. 
The channel pattern was transferred by ultraviolet exposure 
from the negative film to the photoresist layer on the glass 
sheet. After the pattern transfer, the glass plate was baked in 
an oven at 80°C overnight (∼17 hours) to dry and harden the 
mask on glass. The channels were then etched using 1% hydro-
fluoric acid (Sigma-Aldrich) buffered with 5% ammonium 
fluoride (Sigma-Aldrich) solution at 65°C under ultrasonic 
agitation (Ultrasonic Bath; VWR International, Lutterworth, 
Leicestershire, United Kingdom). Finally, the etched glass 
was thermally bonded (595°C for 3 hours) to a top glass 
plate into which outlet and inlet holes had been previously 
drilled to link the channels. Teflon tubes (Upchurch Scientific, 
Oak Harbor, WA) with an inner diameter of 500 µm were used 
to connect the reactor to gastight glass syringes (Hamilton Com-
pany, Reno, NV) controlled by a KDS syringe pump (KD100; KD 
Scientific Inc, Holliston, MA) for reagent delivery.
Preparation of PMs in microfluidic 
reactor and by bulk mixing
PMs were prepared by the microfluidic approach using a 
microfluidic reactor consisting of three inlets, one main 
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channel, and a single outlet (Figure 1). The  channel 
architecture allowed the creation of a hydrodynamic 
flow focusing configuration. The focusing was generated 
where the central stream of polymer/drug/DMSO solution 
met the two lateral sheath streams of water side-by-side. 
A  photomicrograph of the typical arrow shape liquid 
 focusing is shown in the upper inset of Figure 1. The 
volumetric ratio of the organic solution over water (R) was 
varied by changing the relative flow rates. The dimensions 
(in mM) of the microfluidic reactor are reported in Figure 1. 
All channels had a depth of 30 µm. The channels had a 
semicircular cross-sectional shape so that channel width 
was strictly connected with channel depth, due to the iso-
tropicity of the fabrication procedure.34,35 The flow within 
the microchannels was monitored by an inverted  microscope 
(IX51; Olympus Corporation, Tokyo, Japan). PMs were 
also prepared by bulk mixing. A polymeric solution in 
DMSO, in the presence or absence of MTH, was added 
to 2–10 mL of deionized water in a glass round-bottom 
flask and thoroughly mixed by vortexing for 5 minutes. 
 Different volumetric ratios (R) of organic solution to water 
were selected varying between 0.03 and 0.13. For both 
microfluidic and bulk mixing procedures, the preparation of 
PMs was performed at environmental temperature,  typically 
ranging between 21°C–23°C.
Characterization of PMs
Before characterization, the amount of water was adjusted 
in order to have the same DMSO/water ratio in all samples 
(ie, 3.2% DMSO volume/volume).
The size and size distribution of PMs were determined 
by dynamic light scattering (Zetasizer Nano ZS; Malvern 
Instruments Ltd, Malvern, Worcestershire, United Kingdom) 
and/or by nanoparticle tracking analysis (LM10; NanoSight 
Ltd, Amesbury, Wiltshire, United Kingdom). For each 
measurement, 300 µL of PM suspension was loaded in the 
detection cell and five measurements were performed to give 
an average value using Zetasizer Software 6.12 (Malvern 
Instruments) and nanoparticle tracking analysis (NTA) 
system NanoSight LM10 (NanoSight Ltd, Amesbury, UK). 
PM sizing was performed at environmental temperature, 
typically ranging between 21°C–23°C.
To estimate the amount of drug associated in small 
PMs (ie, mean diameter # 200 nm; PMs
200
) and large PMs 
(ie, mean diameter $ 200 nm), PM suspension, after prepara-
tion, was passed through a 0.2 µm pore size filter, as previously 
reported.36 MTH concentration in filtrates was estimated by 
measuring its fluorescence at λ
ex
 = 440 nm and λ
em
 = 523 nm 
using a Cary Eclipse Fluorescence Spectrophotometer 
(Agilent Technologies, Stockport, United Kingdom). The 
percentage of drug associated in PMs
200
 (drug
200
) was 
calculated using the following equation:
 Drug
200
 = a/b × 100 (1)
where a is the weight amount of drug in PMs
200
 and b is the 
total amount of drug used for PM preparation.
To estimate the drug association, def ined as the 
percentage of PM-MTH, samples were ultraf iltrated 
through a semipermeable membrane with 3000 Da nominal 
molecular weight limit (Amicon® Ultra-4 Centrifugal 
Filter Unit; Millipore Ltd, Watford, United Kingdom) 
for 15 minutes at 1.25 g, to separate water phase from 
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Figure 1 schematic representation of the preparation procedure for polymeric 
micelles by microfluidics. Wf represents the width of the focused stream generated 
when the central stream of Pluronic® F127 (BAsF Chem Trade gmbh, Burgbernheim, 
germany) (unimers) and mithramycin dissolved in dimethyl sulfoxide and the two 
lateral sheath streams of water met at the channel junction. The right upper drawing 
reports the dimensional characteristics of the glass microfluidic device. The lower 
graph depicts the formation mechanism of mithramycin encapsulated in polymeric 
micelles in microfluidic environment, showing how the progressive mutual diffusion of 
dimethyl sulfoxide and water molecules causes the unimers to orientate themselves 
so that the hydrophobic blocks are removed from the aqueous environment forming 
the primary polymeric micelle’s nuclei. As the dimethyl sulfoxide/water diffusion 
proceeds, polymeric micelles grow to their final structure and size (see detailed 
explanation in results and discussion section). 
Abbreviations: DMsO, dimethyl sulfoxide; MTh, mithramycin; PM, polymeric 
micelle.
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micelles. The amount of free MTH in the ultrafiltrate was 
determined by spectrofluorimetric analysis at λ
ex
 = 440 nm 
and λ
em
 = 523 nm.
experimental design and statistics
The influence of experimental parameters on the PM size 
and drug
200
 was studied by design of experiments (DoE) 
approach consisting of eleven runs. The experimental design 
and evaluation of the experiments were performed by the 
 software MODDE 8.0 (Umetrics AB, Umea,  Sweden), 
 followed by multiple linear regression algorithms, as 
 previously described.37
K562 cells
K562 cells were cultured in humidified atmosphere of 5% car-
bon dioxide in Roswell Park Memorial Institute-1640 medium 
(Sigma-Aldrich) supplemented with 10% fetal bovine serum 
(Celbio SpA, Milan, Italy), 50 U/mL penicillin, and 50 µg/
mL streptomycin. Treatment of K562 cells with free MTH 
(dissolved in DMSO at the appropriate concentrations) or PM-
MTH was carried out by adding the appropriate concentration 
of drug at the  beginning of the  cultures (cells were seeded at 
30,000/mL). The medium was not changed during the entire 
induction study. The proportion of benzidine-positive cells 
(which contain hemoglobin, an index of erythroid differentia-
tion) was determined after 7 days in culture using a solution 
containing 0.2%  benzidine in 5 M glacial acetic acid (10% 
hydrogen peroxide), as  previously described.8
erPC cultures
Patients were from Thalassemic Day Hospital, S Anna Hos-
pital, University of Ferrara, Ferrara, Italy; written informed 
consent was obtained from each patient and the samples of 
peripheral blood were collected just before the transfusion 
treatment. Mononuclear cells were isolated by Ficoll-Hypaque 
density gradient centrifugation and seeded in α-minimal 
essential medium supplemented with 10% fetal bovine 
serum (Celbio), 1 µg/mL cyclosporine A (Sandoz, Basel, 
Switzerland) and 10% conditioned medium from the 5637 
bladder carcinoma cell line. The cultures were incubated 
at 37°C, under an atmosphere of 5% carbon dioxide in air 
with extra humidity. After 7 days incubation in this phase I 
culture, the nonadherent cells were harvested, washed, and 
then cultured in fresh medium composed of α-medium, 30% 
fetal bovine serum, 1% deionized bovine serum albumin, 
10–5 M β-mercaptoethanol, 1.5 mM L-glutamine, 10–6 M 
dexamethasone, 1 U/mL human recombinant erythropoietin 
(Tebu-bio, Milan, Italy), and stem cell factor (Inalco, Milan, 
Italy). This part of the culture is referred to as phase II. After 
phase II, the induction period with erythroid inducer MTH 
was usually 4 days.
rNA extraction and real-time 
quantitative reverse transcription-
polymerase chain reaction (rT-PCr)
Cells were isolated by centrifugation at 1500 rpm for 
10 minutes at 4°C, washed in phosphate buffered saline, 
and lysed in TRI Reagent® TM (Sigma-Aldrich), according 
to the manufacturer’s instructions. The isolated RNA was 
washed once with cold 75% ethanol, dried, and dissolved in 
diethylpyrocarbonate-treated water before use. RT-PCR was 
performed as follows. After production of complementary 
DNA, using 1 µg total RNA, a control PCR for γ-globin 
gene expression was performed using the γ-globin mRNA-
specific primers 5′-ACTCGCTTCTGGAACGTCTGA-3′ and 
5′-AGTGCCCTGTCCTCCAGATAC-3′. Quantitative real-
time PCR assay of γ-globin mRNA, β-globin, and α-globin 
transcripts were carried out using gene-specific double 
fluorescent-labeled probes in a 7700 Sequence Detection 
System version 1.6.3 (Applied Biosystems, Warrington, 
Cheshire, United Kingdom). The following primer and probe 
sequences were used for real-time PCR: γ-globin forward primer, 
5′-TGGCAAGAAGGTGCTGACTTC-3′; γ-globin reverse 
primer, 5′-TCACTCAGCTGGGCAAAGG-3′; γ-globin 
probe, 5′-FAM-TGGGAGATGCCATAAAGCACCTGG 
TAMRA-3′; β-globin forward primer, 5′-CAAGAAAGT 
GCTCGGTGCCT-3 ′ ;  β -g lob in  reverse  p r imer, 
5′-GCAAAGGTGCCCTTGAGGT-3′; β-globin probe, 
5 ′ -FAM-TAGTGATGGCCTGGCTCACCTGGAC 
TAMRA-3′; α-globin forward primer, 5′-TCCCCACCAC 
C A AG AC C TAC - 3 ′ ;  α - g l o b i n  r eve r s e  p r i m e r, 
5 ′ - C C T TA AC C T G G G C AG AG C C - 3 ′ ;  α - g l o b i n 
probe, 5′-FAM-TCCCGCACTTCGACCTGAGCCA 
TAMRA-3′. The fluorescent reporter and the quencher were 
6-carboxyfluorescein (FAM) and 6-carboxy-N,N,N′,N′-
tetramethylrhodamine (TAMRA), respectively. For real-time 
PCR of the reference genes, the endogenous control human 
glyceraldehyde-3-phosphate dehydrogenase was used, and 
β-actin kits and the probes were fluorescently labeled with 
Taqman® VIC dye (Applied Biosystems).
high performance liquid chromatography 
(hPLC) analysis of hemoglobin
ErPC were harvested, washed once with phosphate buffered 
saline, and the pellets were lysed in lysis buffer (sodium 
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dodecyl sulfate 0.01%). After incubation on ice for 15 minutes, 
and spinning for 5 minutes at 14,000 rpm in a microcentrifuge, 
the supernatant was collected and injected. Hemoglobin 
present in the lysate was separated by cation-exchange 
HPLC,38 using a System Gold 126 Solvent Module-166 
Detector (Beckman Coulter Ltd, High Wycombe, United 
Kingdom). Hemoglobin was separated using a Syncropak 
CCM 103/25 (250 mM × 4.6 mM) column (Rotork, Bath, 
United Kingdom), samples were eluted in a solvent gradient 
using aqueous sodium acetate-Bis Tris-potassium cyanide 
buffers, and detection was performed at 415 nm. The standard 
controls were purified adult hemoglobin (Sigma-Aldrich) and 
HbF (Alfa Wassermann, Milan, Italy).
statistical data analysis
All the data were normally distributed and presented as 
mean ± standard deviation. Statistical differences between 
groups were compared using one-way analysis of variance 
between groups. Statistical significance was assumed at 
P values less than 0.05 or 0.001.
Results and discussion
Production of PMs by microfluidics: 
general considerations and mechanism  
of PM formation
Nanotechnology has considerable potential for the treatment 
of many diseases, due to the opportunity of nanocarriers 
(ie, PMs) to control the temporal and spatial distribution of 
drugs within different organs or tissues. However, nanocarri-
ers for drug delivery require a number of specific requisites, 
such as defined size and size distribution, depending on their 
administration route and therapeutic application.39
In this respect, a series of experiments was started, aimed 
at the production of precisely size controlled PMs by micro-
fluidic approach. The procedure, developed in the authors’ 
laboratory, is reported in Figure 1, together with a scheme 
of the employed microfluidic reactor, the  experimental 
setup, and a drawing illustrating the mechanism of PM 
formation.
In the preliminary step of the procedure, polymer and 
drug are dissolved in DMSO, in which both species are 
molecularly dispersed as either single polymer unimers 
or drug molecules, respectively. The DMSO solution is 
then injected into the microfluidic device where the entire 
formation process (unimer self-assembly in PMs) occurs. 
The employed microfluidic device is characterized by a 
hydrodynamic flow focusing configuration (Figure 1) in 
which the central stream of polymer and drug in DMSO 
solution flowing along the main channel is hydrodynamically 
focused when it meets two lateral sheath streams of water 
side-by-side.
As DMSO comes in contact with water, the mutual 
diffusion of DMSO and water molecules causes a progressive 
increase of the microenvironment hydrophilicity in which the 
unimers and drug reside (ie, due to water content rise). As a 
consequence of the microenvironment change, the unimers 
orientate themselves so that the hydrophobic blocks are 
removed from the aqueous environment in order to achieve 
a state of minimum free energy.17,39 This process causes the 
nucleation of unimers forming the primary PM’s nuclei.40 It 
is likely that at this stage MTH molecules move towards the 
nascent PMs, which represent an environment suitable for 
MTH solubilization, as proved by the MTH partition water/
octanol partition coefficient (log P = 1.290 ± 1.454).26 As 
the DMSO/water diffusion proceeds, in parallel, PMs grow 
to their final structure and size.17
The reciprocal diffusion of solvent molecules represents 
the crucial step of micelle formation, thereby controlling 
the self-assembly process and size characteristics of the 
produced PMs. For instance, it has been demonstrated that 
slowing the rate of organic solvent removal led to larger and 
polydispersed PMs.40 On the other end, a fast and uniform 
solvent displacement, achievable in microfluidic device, is 
beneficial in controlling the self-assembly process, leading to 
small PMs with a narrow size distribution.30 It is noteworthy 
that, within the microfluidic device, the organic solvent (ie, 
DMSO) removal process is mainly controlled by the width 
of the focused stream (W
f
), which is in turn controlled by the 
volumetric flow ratio between central (ie, DMSO solution) 
and sheath (ie, water) streams.
With respect to the choice of amphiphilic polymer for the 
production of PMs, the well-known Pluronic F127 polymer 
was chosen on the basis of the following consideration. 
Pluronic block copolymers can be suitably employed for the 
production of the drug delivery system with multiple effects.41 
The incorporation of drugs into PMs formed by Pluronic 
results in enhanced metabolic stability and circulation 
time, with beneficial effects in increasing drug efficacy and 
lowering side effects. In addition, Pluronic F127, thanks to 
its well-studied characteristics and impressive safety profile, 
was Food and Drug Administration approved for pharma-
ceutical and medical applications, including parenteral 
administration.33
Keeping in mind all these considerations, the initial 
part of the current study was devoted to the investiga-
tion of the experimental conditions influencing the size 
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and size distribution of the produced PMs. The analysis 
was  performed by a changing-one-separate-factor-a-time 
(COST) approach, which represents an intuitive method 
of experimental design involving the testing of factors, or 
causes, one at a time instead of all simultaneously. Prominent 
text books and academic papers currently favor factorial 
experimental designs, where multiple factors are changed 
at once.42,43 Despite this criticism, some researchers have 
demonstrated that the practical information you can obtain 
by COST can be later employed for a successive DoE. In 
fact, informative DoE results are generally obtained when 
there is good knowledge of the investigated system. COST 
approach permits the selection of the factors that affect the 
process and the reduction of process variability.43
It should be also noted that, from a practical point of 
view, the experimental approach based on microfluidics is 
intrinsically simple and mainly governed by few experimental 
parameters (factors). The factors involved in the production 
of PMs by microfluidics are generally limited to: (a) size of 
the channel of the microfluidic device, (b) total flow rate, 
(c) volumetric ratio (R) between polymeric solution and 
water, (d) concentration of polymer, and (e) concentration 
of drug.30,32 With respect to channel size and total flow rate, 
previous investigations have demonstrated that it is possible 
to produce PMs in a robust and reproducible fashion when 
using a microfluidic device similar in size (channels) to that 
employed for the present investigation and a total flow rate 
of 0.65 mL/minute.44
For these reasons, attention was focused on a reduced 
number of experimental parameters that are most likely to 
influence PM-MTH self-assembly, including volumetric ratio 
R and polymer and MTH concentration.
Effects of microfluidic parameters  
on PM characteristics
As a first parameter, the volumetric flow ratio R was 
 considered. It represents the volumetric ratio between the 
liquid flowing in the central channel (polymer/drug/DMSO) 
and that flowing in the two lateral channels (water). R is 
strictly related to the mixing time between solvent/ nonsolvent 
(DMSO/water) which represents the key step in the pro-
duction of PMs by microfluidics.30 The effect of R was 
analyzed by varying its values in the range between 0.03 
and 0.13. Pluronic F127 concentration within the DMSO 
inlet stream was set at 7.5 mM. The results reported in 
Figure 2 shows that PMs produced by microfluidic reactor 
have a mean radius 52–61 nm, and the R value positively 
correlates with PM size. For comparison, the dimensional 
data referring to PMs produced by conventional bulk mixing 
procedure (using the same chemical composition) are also 
displayed. Figure 2 shows there is significant difference in 
the relationship between PM mean size and R exhibited by 
the two production methods. In the microfluidic system, PM 
size increases approximately linearly with an R increase, 
while on the contrary no clear correlation can be found for 
the bulk procedure. PMs produced by microfluidics display 
a smaller mean diameter (52–61 nm) in comparison to those 
by conventional bulk mixing (65–74 nm). In addition, the 
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Figure 2 effect of the volumetric ratio between dimethyl sulfoxide (solubilizing 
Pluronic® F127 [BAsF Chem Trade gmbh, Burgbernheim, germany]) and water 
phase on polymeric micelle mean size (A) and size distribution (B). Polymeric micelles 
were produced by the microfluidic device depicted in Figure 1 (microfluidics) (filled 
bars and circles) and, for comparison, by conventional bulk mixing (conventional) 
(open bars and circles) at the reported r values. Pluronic F127 concentration was 
kept constant at 7.5 mM for all experiments. 
Note: Data represent the average of three independent experiments (run in 
triplicate) ± standard deviation. 
Abbreviations: DMsO, dimethyl sulfoxide; PM, polymeric micelle; r, volumetric 
ratio of organic solution to water.
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use of microfluidic reactors resulted in the production of 
PMs with significantly lower polydispersity (Figure 2B). 
The superior dimensional characteristics of PMs obtained 
by microfluidics were attributed to the controlled removal of 
DMSO in a precise fashion. This feature was feasible thanks 
to the fast and adjustable mixing process within microfluidic 
channels. In contrast, PMs prepared by the conventional 
procedure present a much broader dimensional distribution 
as demonstrated by the thick tail present in the frequency 
distribution curve (Figure 2B).
Further evidence of the superior controllability and repro-
ducibility of microfluidics is demonstrated by the smaller 
standard deviation of the mean radius in PMs produced by 
microfluidics as compared with those produced by conven-
tional procedure (Figure 2A). In addition, the results from 
different runs in the microfluidic system showed only a 
small variation in size (±3 nm compared to ±11 nm from 
bulk systems), demonstrating the robustness of microfluidic 
production in terms of controllability and reproducibility.
effects of polymer concentration  
on PM characteristics
The initial polymer concentration represents another 
important parameter to be considered especially for drug 
delivery applications. It is well know that PM in vivo 
 stability is related to both polymer concentration and critical 
 micellization concentration. In this respect, it should be 
considered that PMs after intravenous administration undergo 
dilution by circulating blood, usually about 25-fold, in the 
case of a bolus injection.39
Therefore, the effects of polymer concentration and 
hydrodynamic flow focusing conditions on PM size were 
examined. Polymer concentrations were selected in order to 
be sufficiently high to prevent, after administration, a possible 
premature disassembly of PMs and the consequent release 
of the contained drug. An initial polymer concentration 
ranging between 7.5–15.0 mM was employed, giving a final 
concentration of 1.0–2.0 mM (at R = 0.13); notably, these 
values are about 15–30 times higher than Pluronic critical 
micellization concentration (69 µM).45
Different polymer concentrations resulted in PMs with 
a similar dimensional trend that corresponded with increas-
ing R; only slightly larger dimensions occurred for PMs 
produced at high polymer concentration (15.0 mM). This 
small but appreciable effect has been tentatively attributed 
to the viscosity increase of the polymeric solution, which 
increased from 9.1 ⋅ 10–3 to 28.2 ⋅10–3 Pa⋅second. As a result, 
the mixing process was consistently slowed down, due to a 
smaller diffusion coefficient; this effect allowed the unimer 
aggregation to take place for a longer time, resulting in 
slightly larger PMs.44 In contrast, no significant differences 
were observed for the size distributions of PMs produced at 
low or high polymer concentrations (Figure 3B–D).
effects of MTh encapsulation  
on PM characteristics
Figure 4 reports the dimensions of PMs produced by 
 microfluidics or bulk mixing in the presence of different 
concentrations of MTH: 10.0 µM, 32.5 µM, and 55.0 µM; 
R = 0.03. Pluronic F127 concentration was kept constant at 
15.0 mM for all the experiments. Both preparation procedures 
resulted in the formation of PMs larger in size with respect to 
their empty counterparts. This result could be explained by 
the intercalation of MTH molecules (possessing amphiphilic 
properties) within the polymer chains into the core/shell inter-
facial region of the micelles.46 The presence of “guest” drug 
molecules is likely to decrease on one side of the interactions 
between unimers during the PM aggregation process40 and on 
the other side to increase interfacial surface area.47 However, 
how MTH and, in general, a nonprecipitating amphiphilic 
molecule interferes with the PM’s precipitation process is 
beyond the scope of this manuscript and remains the subject 
of future research.
At concentration of 55.0 µM, MTH caused an increase 
in PM mean radius from 56 nm to 61 nm and from 75 nm 
to 98 nm for microfluidic and conventional procedures, 
respectively (Figure 4). As is clearly evident, MTH had a 
notable effect especially during the bulk mixing procedure, 
where it caused the formation of a thick tail of PMs with a 
characteristic radius above 120 nm. In contrast, it caused 
only a small increase in the size of PM-MTH produced 
by microfluidics whereas the three MTH concentrations, 
that employed more than 90% of the produced PMs, had 
a characteristic radius below 110 nm. Furthermore, the 
lower interbatch standard deviation found for microfluidic 
samples indicated higher reproducibility of the method 
(2.5–5.5 nm and 6.0–20.0 nm for microfluidic and conven-
tional procedures, respectively).
The determination of drug association showed that 
MTH is preferentially partitioned in the micellar phase. 
Specifically, determinations in the present study demon-
strated that about 85% and 83% (weight/weight) of the total 
MTH is associated to the micellar phase for microfluidics and 
bulk mixing preparation procedures, respectively. This result 
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is supported by the drug log P (1.290 ± 1.454), indicating 
the slight lipophilic nature of MTH molecule.26
Optimization of PM-MTh production  
by Doe approach
In order to comparatively study the influence of experimental 
parameters on PM characteristics produced by microfluidic 
versus conventional bulk mixing, a statistical data analysis 
based on a DoE approach was performed.
The DoE approach used was a full factorial design plus 
two center points. It studies the effects of design variables 
independently from each other, including interaction terms. 
Full factorial designs include enough experiments to allow 
use of a model with all interactions. Thus, they are a  logical 
choice if one intends to study interactions in addition to 
main effects.
From the initial COST results (Figures 2–4), previous 
studies, and as already discussed, two factors were included 
in the DoE approach to study their effect on the characteristics 
of PMs, namely R and drug concentration.30,44
The response variables and their target ranges were 
selected, taking into consideration that it is well-established 
that size and size distribution are major factors determining 
the pharmacokinetic and biodistribution of PMs in vivo.20,31,48 
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Figure 3 effect of Pluronic® F127 (BAsF Chem Trade gmbh, Burgbernheim, germany) concentration and r on polymeric micelle mean size (A) and size distribution (B–D). 
Polymeric micelles were produced by microfluidics, at the reported R values, using a 7.5 mM (striped bar, open circles) and 15.0 mM (filled bars and circles) Pluronic F127 
solution. 
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Typically, PMs with mean radius 50–100 nm maximize 
stealth properties, reducing recognition by immune system 
components with prolonged plasma circulation times, as 
compared to those with larger diameter.16,17,21,49,50 In addition, 
PMs larger than 200 nm in diameter have been demonstrated 
to be removed from circulation by spleenic filtration at 
interendothelial cell slits.50–53 Taking into account the above 
reported consideration, the goal was to obtain PMs with sizes 
50–100 nm in radius, a size distribution as narrow as possible, 
and a high drug
200
. Particularly, the response factor drug
200
 
was taken into consideration to estimate the amount of drug 
associated in PMs larger than 200 nm in diameter.
The experiments were designed to simultaneously 
investigate the effects of the factors (R and concentration) 
on the responses (size, standard deviation, and drug
200
) (see 
explanations in Table 1). Each factor was tested at three 
levels and two additional center points were added, in order 
to get an estimation of the experimental error. In Table 2 and 
Figure 5 the complete list of experimental data and results 
are reported.
The mathematical equation employed for the 32 full 
factorial design was:
 y = A
0
 + A
1
concentration + A
2
R + A
3
concentration ⋅ R (2)
where A
o
 represents the global mean and A
1
 represents the 
other regression coefficients.
Three-dimensional graphs (Figure 5) show the fac-
tor influence on size, standard deviation, and drug
200
 of 
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Abbreviations: MTh, mithramycin; PM, polymeric micelle.
International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
317
Mithramycin encapsulated in polymeric micelles
PMs produced by microfluidics (red surfaces) versus 
conventional bulk mixing (green surfaces). The reported 
results (see also Table 2) indicate the superior overall 
quality of PMs  produced by microfluidics. Indeed, the 
red surfaces show a better quality of the produced PMs in 
terms of size, standard deviation, and drug
200
. Specifically, 
for the microfluidic protocol, a clear trend of the factor 
effects on the size characteristics has been found: an 
increase in the factor R from low to high level (0.03–0.13) 
resulted in a moderate increase in the response size 
that rose from about 60 nm to around 90 nm, while the 
response standard deviation remained almost constant, 
with only a slight increase as a result of increased R and 
concentration.
These results clearly demonstrated the precise control 
over the mixing under laminar flow conditions, resulting in 
predictable continuous flow preparation of PMs of controlled 
size (Figure 5A and B). In contrast, the bulk mixing led to 
a lack of a dimensional correlation between experimental 
parameters and PM size; it is indeed evident that the bulk 
mixing caused the formation of large and polydisperse PMs. 
The limited size control is likely due to the chaotic nature of 
mixing under the turbulent conditions associated with bulk 
mixing procedures.
The analysis of drug
200
 gives a coarse indication of the 
percentage of drug that is associated in small PMs, which 
can be taken up by the cells through nonphagocytic trans-
location. In this respect, it has been shown that a reduction 
of size was a critical factor to improve such mechanism of 
translocation within blood cells.32 The concentration factor 
deeply influences this response; specifically, an increase of 
concentration was accompanied by a decrease of drug
200
 
(Figure 5C and Table 2) for PM-MTH produced with bulk 
mixing. In contrast, the microfluidic-based procedure is 
much less affected by the loss of drug during the filtration 
step, as evident by the higher value for drug
200
. As a general 
explanation of the drug
200
 trend, the progressive rise of MTH 
molecules  probably causes the formation of an increasing 
number of large PM-MTH aggregates. Interestingly, at the 
same concentration level, the micelles produced by bulk 
mixing at different R show a similar drug
200
, indicating that 
R has only a minor effect on drug
200
 for this preparation 
procedure.
Once again, the microfluidic procedure shows superior 
control over the final micelle characteristics; for instance, the 
highest drug
200
 is achieved at an intermediate R value (0.08). 
The authors believe that this effect could be related to the 
complex interactions between molecular and hydrodynamic 
phenomena occurring during the micelle assembly, even if, 
at this stage, there is no sufficient experimental evidence to 
corroborate this hypothesis.
The DoE analysis also offers indications for the 
development of a robust preparation procedure that is of 
primary importance for the therapeutic application of PMs, 
where an efficient control of the PMs’ characteristics is 
required to achieve an optimal and reproducible therapeutic 
efficacy. In this respect, the validity and significance of the 
DoE model was assessed by analysis of variance. Table 3 
reports the percentage of the variation of response explained 
by the model (R2) and the model reproducibility for both bulk 
and microfluidic mixing procedures. The reported results 
demonstrate that all the obtained experimental data fit well 
with the model, indicating good reproducibility. Moreover, 
the high values of both coefficients indicate that the model has 
good validity (R2) and significant reproducibility, especially 
in the case of PMs produced by microfluidics.
Table 1 Design of experiments study of the influence of experimental parameters on the PM characteristics: investigated factors and 
responses
Parameter Abbreviation Meaning Range
Factor
Volumetric ratio r The volumetric ratio between the polymeric solution in DMsO  
and water phase
0.03–0.13
Mithramycin concentration Conc The concentration of the MTh solution in DMsO, employed  
for the PM production
10.0–55.0 µM
Responses
Polymeric micelle size size The mean diameter of polymeric micelle containing MTh as  
determined by dynamic light scattering
standard deviation of polymeric  
micelle size
sD The standard deviation of the mean diameter of polymeric  
micelle containing MTh
Mithramycin in polymeric  
micelles ,200 nm
Drug200 The percentage of drug encapsulated in polymeric micelles  
with a mean diameter #200 nm
Abbreviations: MTh, mithramycin; DMsO, dimethyl sulfoxide; PM, polymeric micelle.
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effect of PM-MTh on proliferation  
and differentiation of K562
After DoE analysis, the optimal formulation (R = 0.03 and 
concentration = 32.5 µM) was selected due to the small size 
and dimensional homogeneity of the produced PM-MTH. 
Such formulation was tested in vitro to investigate its bio-
logical activity and effectiveness as potential treatment for 
β-thalassemia. For comparison, PM-MTH produced both 
by conventional bulk mixing and microfluidic procedures 
were considered.
K562 cells, derived from a patient with chronic myeloid 
leukemia in terminal blast cell crisis, exhibit erythroid fea-
tures and can be induced to produce embryonic and fetal, 
but not adult, hemoglobin. Therefore, such a cell line can be 
conveniently employed as model for studying hemoglobin 
production upon induction to differentiation.7 In this respect, 
it was initially determined, as reported in Figure 6, whether 
Table 3 Analysis of variance of the model
Responses N R2 Reproducibility
Direct mixing
size 11 0.632 0.445
standard deviation 11 0.576 -0.445
Drug200 11 0.845 0.987
Microfluidic mixing
size 11 0.831 0.992
standard deviation 11 0.646 0.098
Drug200 11 0.916 0.999
Abbreviations: Drug200, percentage of drug associated in polymeric micelles with 
diameter # 200 nm; N, number of experiments; r2, percentage of the variation of 
the response explained by the model.
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Figure 5 Design of experiments analysis of the preparation of mithramycin 
encapsulated in polymeric micelles. response surface plots for mithramycin 
encapsulated in polymeric micelles obtained by microfluidics (red surfaces) or 
conventional bulk mixing (green surfaces). The following factors and responses were 
respectively investigated: concentration and r versus size (A), concentration and 
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Table 2 experimental design matrix and results of the design of 
experiments approach for the preparation of mithramycin based 
on polymeric micelles
Run Factors Responses
Concentrationa Rb Sizec Standard  
deviationd
Drug200
e
Microfluidics
#1 10.0 0.3 60.0 21.0 77.0
#2 55.0 0.3 61.0 22.0 58.6
#3 10.0 0.13 81.0 23.0 92.3
#4 55.0 0.13 90.0 28.0 48.1
#5 10.0 0.08 69.0 21.0 89.8
#6 55.0 0.08 71.0 23.0 55.3
#7 32.5 0.03 62.0 22.0 84.7
#8 32.5 0.13 73.0 24.0 65.0
#9 32.5 0.08 76.0 25.0 86.8
#10 32.5 0.08 74.0 21.0 86.4
#11 32.5 0.08 75.0 26.0 87.0
Bulk mixing
#1b 10.0 0.3 94.0 47.0 72.3
#2b 55.0 0.3 97.0 56.0 35.0
#3b 10.0 0.13 92.0 36.0 79.7
#4b 55.0 0.13 106.0 37.0 35.8
#5b 10.0 0.08 109.0 67.0 76.1
#6b 55.0 0.08 100.0 52.0 49.2
#7b 32.5 0.03 105.0 70.0 59.1
#8b 32.5 0.13 123.0 52.0 49.2
#9b 32.5 0.08 120.0 73.0 38.7
#10b 32.5 0.08 106.0 55.0 34.9
#11b 32.5 0.08 110.0 49.0 37.5
Notes: aConcentration (µM) of the mithramycin solution in dimethyl sulfoxide 
employed for production of polymeric micelles; bvolumetric ratio between 
the polymeric solution in dimethyl sulfoxide and water phase; cmean radius of the 
obtained polymeric micelles as determined by dynamic light scattering (nm); dstandard 
deviation of the mean radius measurements (n = 5, each measured in quintuplicate); 
epercentage of drug associated in polymeric micelles with diameter #200 nm.
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PM-MTH could affect the proliferation of K562 cells 
when employed at the concentrations exhibiting effects on 
differentiation. For comparison, Figure 6 reports the data 
obtained by the free drug. Cells were cultured for 3 days in 
the presence of the indicated concentrations of MTH, then 
added to the culture medium in form of free drug or encap-
sulated into PMs, and prepared by microfluidics or bulk 
mixing procedures. As shown by the proliferation versus 
MTH concentration graph, when the drug is employed in 
the range of concentrations comprised between 6–50 nM, 
it had only a limited effect on cell proliferation (,35%). 
K562 cells cultured in the presence of Pluronic F127-empty 
PMs (ie, without drug), prepared with the same chemical 
composition and using an identical experimental setup 
used for the production PM-MTH,  displayed a viability and 
proliferation rate superimposable to the untreated control 
cells (data not shown).
Notably, the delivery by PM-MTH appears to have 
a positive effect on the cytotoxic activity of the drug. In 
fact PM-MTH for all the tested concentrations presented a 
slightly less pronounced effect on cell growth, with respect 
to the free drug. After having demonstrated that free MTH 
and PM-MTH, at concentrations below 50 nM, presented 
no significant inhibitory activity on cell growth, the ability 
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Figure 6 effect of mithramycin on growth of K562 cells. Microphotographs showing K562 cell density after 3 days of culture in the absence (control) or presence of the 
indicated mithramycin concentrations (nM). Corresponding graph: free mithramycin (squares), mithramycin encapsulated in polymeric micelles prepared by microfluidics 
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of PM-MTH to induce the erythroid differentiation of 
K562 cells was tested. Figure 7 shows that cell treatment 
at the indicated concentration of free MTH and PM-MTH 
induced a clearly evident erythroid differentiation, as proved 
by the intense positive blue color developed by the cells after 
benzidine staining, which indicates hemoglobin production 
(Figure 7A and B). Empty Pluronic F127 micelles, used as 
control, did not show any appreciable difference in cell dif-
ferentiation when compared with untreated cells (data not 
shown). Notably, the delivery by micelles produced by micro-
fluidics appears to have a positive effect on the differentiative 
activity of MTH, In fact, at 50.0 nM PM-MTH presented a 
slightly more pronounced differentiation, with respect to free 
drug (microfluidics versus free MTH P , 0.05). However, 
benzidine staining indicates whether a single cell is undergo-
ing erythroid differentiation and hemoglobin production, it 
does not give information on the levels of induction, in terms 
of accumulation of globin mRNA and hemoglobin within 
single benzidine-positive cell populations.
In order to obtain quantitative results and additional 
information at the molecular level, RT-PCR was performed, 
for the analysis of α- and γ-globin mRNA expression levels 
(Figure 7C). The quantification of β-globin mRNA was not 
performed, since it is known that the β-globin gene is not 
efficiently transcribed in K562 cells.54 The obtained results 
indicate that microfluidic-prepared PM-MTH are more 
active in inducing α- and γ-globin mRNA accumulation 
when compared to free MTH or PM-MTH prepared by bulk 
mixing (α-globin: microfluidics versus bulk P , 0.001, 
microfluidics versus free MTH P , 0.05; γ-globin: micro-
fluidics versus bulk P , 0.05, microfluidics versus free 
MTH P , 0.05).
Smaller dimensions of the microfluidic-produced PM-
MTH, as compared with those produced by bulk procedure 
(Figure 5C and Table 2), might be the reason for more 
efficient cell internalization through nonphagocytic trans-
location mechanism, resulting in higher intracellular MTH 
concentration and relatively higher differentiative activity. 
Further investigations are underway in the authors’ laboratory 
to elucidate the mechanism of this effect.
effect of PM-MTh on erPCs
As further investigation, it was analyzed whether MTH 
delivered by microfluidic-produced PM-MTH are able 
to stimulate HbF production in erythroid progenitor cells 
from β-thalassemia patients. ErPC were stimulated with 
erythropoietin in the absence of MTH (uninduced ErPC) 
or in the presence of MTH (either free drug or PM-MTH), 
Figure 7 effect of mithramycin on erythroid differentiation of K562 cells 
(A and B). Cells were cultured for 7 days in the presence of the indicated mithramycin 
concentrations (nM), then added to the culture medium in form of free drug or 
associated in polymeric micelles, and prepared by microfluidics or conventional bulk 
mixing. (A) Microphotographs were taken after benzidine staining of cells treated 
with mithramycin encapsulated in polymeric micelles (microfluidics); thereafter 
cells were counted and the percent of benzidine-positive cells was determined and 
plotted. scale bar 25 μm. (B) Data represent the average of three independent 
experiments (run in triplicate) ± standard deviation (microfluidics versus free 
mithramycin P , 0.05). (C) effects of mithramycin on expression of globin genes. 
Cells were cultured for 4 days in the presence of mithramycin (50 nM), then added 
to the culture medium in form of free drug or associated in polymeric micelles, 
and prepared by microfluidics or conventional bulk mixing. Reverse transcriptase-
polymerase chain reaction was performed for quantification of α-globin (open bars) 
and γ-globin (filled bars) messenger ribonucleic acid sequences. 
Notes: Data represent fold content in respect to control uninduced cells (average ± 
standard deviation of three independent experiments); α-globin: microfluidics versus 
conventional P , 0.001, microfluidics versus free mithramycin P , 0.05; γ-globin: 
microfluidics versus conventional P , 0.05, microfluidics versus free mithramycin 
P , 0.05.
Abbreviations: MTh, mithramycin; mrNA, messenger ribonucleic acid.
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Figure 8 Effect of mithramycin encapsulated in polymeric micelles prepared by microfluidics on fetal hemoglobin production by erythroid precursor cells from a β-thalassemia 
patient. erythroid precursor cells were cultured in phase II with only erythropoietin, or erythropoietin plus free mithramycin, or mithramycin encapsulated in polymeric 
micelles prepared by microfluidics. (A) High performance liquid chromatography profile of uninduced erythroid precursor cells (left), erythroid precursor cells induced 
by mithramycin encapsulated in polymeric micelles (center), and free mithramycin (right). (B) Quantitative effects on fetal hemoglobin and the production of α-aggregates 
in erythroid precursor cells induced by mithramycin encapsulated in polymeric micelles (filled bars) and free mithramycin (grey bars). For comparison, data for uninduced 
erythroid precursor cells (open bars) are also reported (fetal hemoglobin: uninduced versus microfluidics P , 0.05, uninduced versus free mithramycin P , 0.05; α-aggregates: 
uninduced versus microfluidics P , 0.001, uninduced versus free mithramycin P , 0.001, microfluidics versus free mithramycin P , 0.05). (C) reverse transcriptase-
polymerase chain reaction analysis of erythroid precursor cells expressed as fold induction of α-globin, β-globin, and γ-globin messenger ribonucleic acid production. Cells 
were treated with mithramycin encapsulated in polymeric micelles (black bar) or free drug (grey bars). 
Note: Data represent the average of three independent determinations ± standard deviation. 
Abbreviations: hbA, adult hemoglobin; hbF, fetal hemoglobin; min, minutes; MTh, mithramycin; mrNA, messenger ribonucleic acid.
and the lysates were analyzed by HPLC. As demonstrated 
by Figure 8, an increase of HbF is observed from 17.23% 
(uninduced ErPC) to 22.71% (ErPC treated with PM-MTH). 
As expected, free MTH stimulates an HbF increase (20.35%) 
but to a lower extent. Of interest is the parallel reduction of 
α-globin aggregates which represent 24.39% of the total 
hemoglobin (for uninduced ErPC), both in ErPC treated with 
PM-MTH (6.71%) or free MTH (11.30%) (HbF: uninduced 
versus microfluidics P , 0.05, uninduced versus free MTH 
P , 0.05; α-aggregates: uninduced  versus microfluidics 
P , 0.001, uninduced versus free MTH P , 0.001, micro-
fluidics versus free MTH P , 0.05).
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might be suitable for personalized medicine applications, 
which require controllable PM characteristics and consis-
tency from batch to batch.
These results, representing an important first step in 
clinical development, should be considered with cau-
tion as a possible therapeutic treatment of β-thalassemia 
patients for at least two reasons. First, ErPC isolated from 
β-thalassemia patients exhibit very different starting levels 
of HbF and different response to HbF inducers, includ-
ing MTH.9 Accordingly, the analysis of several patients 
with different (a) genotype, (b) starting levels of HbF, and 
(c) response to hydroxyurea (the most frequently used HbF 
inducer in the therapy of patients affected by β-thalassemia 
and sickle-cell anemia) is required before proposing this 
strategy for β-thalassemia therapy. Second, with respect to 
the toxicity of MTH, two considerations should be made: 
(a) MTH analogs exhibiting safer pharmacological fea-
tures and improved therapeutic index have been recently 
developed55,58 and (b) novel transgenic mouse systems are 
available to study the effects in vivo of either free MTH 
and PM-MTH formulations.59,60 For instance, the recently 
humanized transgenic mice carrying the entire human 
β-globin locus are very appealing for testing possible HbF 
inducers, since this experimental model does not suffer by 
the fact that an HbF-like hemoglobin is not produced by 
normal mice.9
A further consideration is related to possible applica-
tions of PM-MTH to other pathologies including neoplastic 
 diseases.60 In this respect, it would be very interesting to 
verify the activity of PM-MTH on tumor cell lines and in vivo 
tumor cell systems.
Finally, the comparison of the effects of free MTH 
and PM-MTH on the expression of the genome should be 
 evaluated; transcriptomic as well as proteomic analyses 
are now widely used to describe the effects of  therapeutic 
 molecules, including MTH, on the overall genome  expression.
Microarray analysis and proteomic studies will conclusively 
demonstrate whether or not PM-mediated delivery of MTH 
alters the effects on gene expression.
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The decrease of α-globin aggregates following treatment 
with HbF inducers is of a great importance, since the excess 
of α-globin production by β-thalassemia patients is respon-
sible for the clinical symptoms of this pathology. When 
the HPLC results are reported on a cell basis, HbF was 
0.12 ± 0.04 in control cells, 0.24 ± 0.06 in PM-MTH-treated 
cells, and 0.20 ± 0.06 in ErPC treated with free MTH.
These f indings are further sustained by RT-PCR 
analyses on mRNA samples (Figure 8C). No increase of 
α-globin mRNA is observed in both ErPC treated with 
PM-MTH or free MTH, while PM-MTH is able to induce 
γ-globin mRNA (2.87-fold) and β-globin mRNA (1.68-fold) 
more efficiently than free MTH (1.64-fold and 1.14-fold, 
respectively).
Conclusion
A microfluidic-based protocol for the production of a micellar 
delivery system for MTH was developed and examined in 
comparison to micelles produced with conventional methods. 
The effects of different production parameters were investi-
gated and their effects on the size and size distribution were 
statistically evaluated. The results indicate that MTH can 
be efficiently formulated as micellar nanoparticles in a con-
trolled and reproducible manner not achievable by conven-
tional bulk method. After preparation and characterization, 
PM-MTH prepared both by microfluidic and bulk methods 
were tested in vitro to investigate their biological activity 
and effectiveness as potential treatment for β-thalassemia. 
Interestingly, PM-MTH exhibited a slightly lower toxicity 
and more pronounced differentiative activity when compared 
to the free drug. Moreover, the presented data suggest that 
PM-MTH produced by microfluidics is able to induce, at 
high levels, globin mRNA accumulation in K562 cells. Of 
note, the RT-PCR data, obtained using ErPCs, demonstrated 
that PM-MTH, as the most effective HbF inducer, is able 
to induce β-globin and even more efficiently γ-globin gene 
expression without stimulating α-globin gene expression. 
This result is sustained by the HPLC analyses, which showed 
an increase of HbF and a decrease of α-globin aggregates in 
ErPC treated with erythropoietin in the presence of PM-MTH 
produced by microfluidics.
In conclusion, the current paper suggests that PM-MTH 
might be of great interest in inducing HbF in thalassemic 
patients, representing an important first step towards the 
future development of micellar and other nanomedicine-
related therapeutic protocols for β-thalassemia. Also, 
 considering the simplicity and reproducibility of the 
microfluidic technology, the presented production strategy 
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